Informations générales
  • Catégorie de maladie Autre (BASEC)
  • État du recrutement recrutement temporairement en pause (BASEC/ICTRP)
  • Lieu de l’étude
    Genève, Autre
    (BASEC)
  • Responsable de l'étude STIRNEMANN jerome.stirnemann@hcuge.ch (BASEC)
  • Source(s) de données BASEC: Importé de 10.06.2025 ICTRP: N/A
  • Date de mise à jour 10.06.2025 09:55
HumRes55285 | SNCTP000004401 | BASEC2019-01707

Evaluation of hyperbaric oxygen therapy (hyperbaric chamber) in the treatment of vaso-occlusive crisis in sickle cell patients over 8 years old

  • Catégorie de maladie Autre (BASEC)
  • État du recrutement recrutement temporairement en pause (BASEC/ICTRP)
  • Lieu de l’étude
    Genève, Autre
    (BASEC)
  • Responsable de l'étude STIRNEMANN jerome.stirnemann@hcuge.ch (BASEC)
  • Source(s) de données BASEC: Importé de 10.06.2025 ICTRP: N/A
  • Date de mise à jour 10.06.2025 09:55

Résumé de l'étude

This study aims to investigate the treatment with pure oxygen administered under pressure (Hyperbaric Oxygen Therapy or HBO) using a hyperbaric chamber in patients with sickle cell disease presenting to the emergency department for a vaso-occlusive crisis (VOC or acute painful crisis complicating this disease). The principle is to randomly assign patients who will receive the real treatment and those who will receive the placebo. Patients randomized to the intervention arm will receive treatment consisting of a session of hyperbaric oxygen therapy, that is, a session in the chamber with increased pressure and pure oxygen. Patients randomized to the placebo arm will also be treated in the chamber without increasing pressure or using pure oxygen. Neither the patients nor the investigators will know the nature of the treatment received. HBO could currently already be used in sickle cell disease as a consensus conference has recognized its indication, but without being certain of its effectiveness, which must therefore be demonstrated in the VOC, which is the aim of this study. This study should include 100 adult and child patients over 8 years old and should last 2 years. It will take place at two sites: Geneva and Lyon (France). The objective is to rapidly decrease the intensity of pain caused by the VOC and thus allow for a rapid reduction in the doses of morphine typically used in these situations.

(BASEC)

Intervention étudiée

The principle is to randomly assign patients who will receive the treatment with HBO and those who will receive the placebo.

 

All patients will be invited to enter the chamber for about 2 hours, accompanied by a specialized collaborator. They will then receive either the real treatment (increased pressure and pure oxygen) or a placebo (very slight increase in pressure and ambient air instead of oxygen).

The duration of the sessions is 95 minutes (whether in the intervention or placebo arm).

(BASEC)

Maladie en cours d'investigation

Vaso-occlusive crisis in sickle cell patients presenting to the emergency department, occurring in the context of sickle cell disease

(BASEC)

Critères de participation
Patients who meet all of the following criteria may be included in this study: - Patient over 8 years old; - Patient with sickle cell disease. - Patient presenting to the emergency department for a vaso-occlusive crisis not responding to simple analgesics. - Able to perform Valsalva maneuvers (equalizing ear pressure by blowing while pinching the nose and closing the mouth). - Patient who has signed informed consent. (BASEC)

Critères d'exclusion
Patients who meet at least 1 of the following criteria cannot be included: - Current pregnancy; - Indication for artificial ventilation; - Proven contraindication to hyperbaric oxygen therapy established by a hyperbaric physician (a specialized physician will conduct a systematic consultation before any session); - Transcranial Doppler anomaly (> 200 cm/sec) found in the follow-up of children or history of stroke; - Oxygen needs greater than 2 l/min with nasal cannula. (BASEC)

Lieu de l’étude

Genève, Autre

(BASEC)

Lyon (France) Toulouse (France)

(BASEC)

non disponible

Sponsor

Jérôme Stirnemann, HUG

(BASEC)

Contact pour plus d'informations sur l'étude

Personne de contact en Suisse

STIRNEMANN

+41795534408

jerome.stirnemann@hcuge.ch

HUG

(BASEC)

Informations scientifiques

non disponible

Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)

Commission cantonale d'éthique de Genève

(BASEC)

Date d'approbation du comité d'éthique

06.05.2021

(BASEC)


Identifiant de l'essai ICTRP
non disponible

Titre officiel (approuvé par le comité d'éthique)
Evaluation de l’oxygénothérapie hyperbare (caisson hyperbare) dans le traitement de la crise vaso-occlusive chez le patient drépanocytaire de plus de 8 ans (BASEC)

Titre académique
non disponible

Titre public
non disponible

Maladie en cours d'investigation
non disponible

Intervention étudiée
non disponible

Type d'essai
non disponible

Plan de l'étude
non disponible

Critères d'inclusion/exclusion
non disponible

non disponible

Critères d'évaluation principaux et secondaires
non disponible

non disponible

Date d'enregistrement
non disponible

Inclusion du premier participant
non disponible

Sponsors secondaires
non disponible

Contacts supplémentaires
non disponible

ID secondaires
non disponible

Résultats-Données individuelles des participants
non disponible

Informations complémentaires sur l'essai
non disponible

Résultats de l'essai

Résumé des résultats

non disponible

Lien vers les résultats dans le registre primaire

non disponible